Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Momenta Pays Out On Enoxaparin Shut-Out
Settles Class-Action Purchasers’ Suit
Dec 12 2019
•
By
Aidan Fry
Momenta has agreed to pay $35.0m to settle a class-action suit brought by US purchasers of enoxaparin • Source: Shutterstock
More from Legal & IP
More from Generics Bulletin